- Datum30.04.2026
- Uhrzeit17:00 - 17:30 Uhr
- Veranstalter
stock3
Clinuvel Pharmaceuticals Ltd. Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate BSX | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (L&S)
-4,97 %
Intraday
-5,30 %
1 Woche
-8,64 %
1 Monat
-21,03 %
Seit Jahresbeginn
-6,36 %
1 Jahr
-53,22 %
3 Jahre
-68,94 %
5 Jahre
107,82 %
10 Jahre
Passender Service zu Clinuvel Pharmaceuticals Ltd.
Webinar zu Clinuvel Pharmaceuticals Ltd.
Kursinformationen (L&S)
- Tagestief / Hoch (€)-
- 52W-Tief / Hoch (€)4,800-7,630
- Jahrestief / Hoch (€)---
- Schlusskurs (Vortag)
- Eröffnungskurs
Wichtigste Eigenschaften
Dividenden von Clinuvel Pharmaceuticals Ltd.
| Ex-Datum | Fiskaljahr | Dividende | Rendite |
|---|---|---|---|
| - | 2025 | 0,05 AU$ | 0,48 % |
| - | 2024 | 0,05 AU$ | 0,33 % |
| - | 2023 | 0,05 AU$ | 0,28 % |
| - | 2022 | 0,04 AU$ | 0,21 % |
| - | 2021 | 0,025 AU$ | 0,07 % |
| - | 2020 | 0,025 AU$ | 0,12 % |
| - | 2019 | 0,025 AU$ | 0,10 % |
| - | 2018 | 0,02 AU$ | 0,11 % |
Termine von Clinuvel Pharmaceuticals Ltd.
Keine aktuellen Termine
Beschreibung
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
